This report on global angina pectoris treatment market studies various drugs used for treatment of angina pectoris along with pipeline analysis of upcoming potential drugs. Angina is chest pain due to transient myocardial ischaemia, which usually occurs with physical activity or emotional stress, in the United States 10.2 million are estimated to experience angina with approximately 500,000 new cases occurring each year. Thus, drug pipeline of angina pectoris treatment market comprises potential drugs which are specific and fast in therapeutic action.
For the purpose of this study, the various drug classes studied include antiplatelet agents, beta-adrenergic blocking agents, calcium channel blockers, short - long - acting nitroglycerines angiotensin-converting enzyme inhibitors and anti-ischemic agents. Market size estimates and forecast for these segments for the period 2020 to 2030 are provided in terms of USD Mn along with the respective CAGRs for the period 2022 to 2030, considering 2021 as the base year.
The pipeline analysis for angina pectoris treatment market comprises projected market sales of Phase III drugs estimated till 2030. The phase III drugs included in the pipeline analysis are Dantonic/T89 (Tasly Pharmaceuticals, Inc.), RANCAD (TSH Biopharm Corporation Limited), Cilostazol (Korea Otsuka Pharmaceutical Co.,Ltd.), Bococizumab (Pfizer, Inc.), Ticagrelor (J.M. ten Berg/ Astra Zeneca plc), Auto-CD34+ cells (Baxalta US Inc.) and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
For the purpose of this study, the various drug classes studied include antiplatelet agents, beta-adrenergic blocking agents, calcium channel blockers, short - long - acting nitroglycerines angiotensin-converting enzyme inhibitors and anti-ischemic agents. Market size estimates and forecast for these segments for the period 2020 to 2030 are provided in terms of USD Mn along with the respective CAGRs for the period 2022 to 2030, considering 2021 as the base year.
The pipeline analysis for angina pectoris treatment market comprises projected market sales of Phase III drugs estimated till 2030. The phase III drugs included in the pipeline analysis are Dantonic/T89 (Tasly Pharmaceuticals, Inc.), RANCAD (TSH Biopharm Corporation Limited), Cilostazol (Korea Otsuka Pharmaceutical Co.,Ltd.), Bococizumab (Pfizer, Inc.), Ticagrelor (J.M. ten Berg/ Astra Zeneca plc), Auto-CD34+ cells (Baxalta US Inc.) and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.
Historical - Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Angina Pectoris Treatment market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Angina Pectoris Treatment market and their expected impact during the forecast period.Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Angina Pectoris Treatment market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Angina Pectoris Treatment market?
- Which is the largest regional market for Angina Pectoris Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East - Africa?
- Which are the key trends driving Angina Pectoris Treatment market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Angina Pectoris Treatment market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Angina Pectoris Treatment Market
2.2. Global Angina Pectoris Treatment Market, By Drug Class, 2021 (US$ Million)
2.3. Global Angina Pectoris Treatment Market, By Geography, 2021 (US$ Million)
2.4. Impact of Covid 19
2.5. Attractive Investment Proposition by Geography, 2021
2.6. Competitive Analysis
2.6.1. Market Positioning of Key Angina Pectoris Treatment Market Vendors
2.6.2. Strategies Adopted by Angina Pectoris Treatment Market Vendors
2.6.3. Key Industry Strategies
2.6.4. Tier Analysis 2021 Versus 2030
2.7. Key Buying Criteria
2.8. Key Case Reports
2.9. Scenario Analysis
2.9.1. Optimistic estimates and analysis
2.9.2. Realistic estimates and analysis
2.9.3. Pessimistic estimates and analysis
2.10. Market Profiling
2.11. Sales and Marketing Plan
2.12. Top Market Conclusions
2.13. Strategic Recommendations
3. Angina Pectoris Treatment Market: Business Outlook & Market Dynamics
3.1. Introduction
3.2. Global Angina Pectoris Treatment Market Value, 2020 - 2030, (US$ Million)
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.2. Market Restraints
3.3.3. Key Challenges
3.3.4. Key Opportunities
3.4. Impact Analysis of Drivers and Restraints
3.5. See-Saw Analysis
3.6. Porter’s Five Force Model
3.6.1. Supplier Power
3.6.2. Buyer Power
3.6.3. Threat Of Substitutes
3.6.4. Threat Of New Entrants
3.6.5. Competitive Rivalry
3.7. PESTEL Analysis
3.7.1. Political Landscape
3.7.2. Economic Landscape
3.7.3. Technology Landscape
3.7.4. Legal Landscape
3.7.5. Social Landscape
3.8. Heptalysis Analysis
3.9. Critical Investigation of Business Problems Through Five Whys Root Cause Analysis & Relevant Solutions
4. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
4.1. Market Overview
4.2. Growth & Revenue Analysis: 2021 Versus 2030
4.3. Market Segmentation
4.3.1. Antiplatelet agents
4.3.2. Beta-adrenergic blocking agents
4.3.3. Calcium channel blockers
4.3.4. Short & Long - acting Nitroglycerines
4.3.5. Angiotensin-converting enzyme inhibitors
4.3.6. Anti-ischemic agents
4.3.7. Pipeline Analysis
4.3.7.1. Projected sales of Phase III Drugs estimated till 2030 (US$ Mn)
4.3.7.1.1. Dantonic/T89
4.3.7.1.2. RANCAD
4.3.7.1.3. Cilostazol
4.3.7.1.4. Bococizumab
4.3.7.1.5. Ticagrelor
4.3.7.1.6. Auto-CD34+ cells
4.3.7.1.7. Alirocumab
4.3.7.2. Tabular Representation of Phase II and I Drugs
5. North America Angina Pectoris Treatment Market, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
5.3. Angina Pectoris Treatment Market: By Region, 2020-2030, USD (Million)
5.3.1. North America
5.3.1.1. U.S.
5.3.1.1.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
5.3.1.2. Canada
5.3.1.2.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
5.3.1.3. Rest of North America
5.3.1.3.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)6. UK and European Union Angina Pectoris Treatment Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
6.3. Angina Pectoris Treatment Market: By Region, 2020-2030, USD (Million)
6.3.1. UK and European Union
6.3.1.1. UK
6.3.1.1.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
6.3.1.2. Germany
6.3.1.2.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
6.3.1.3. Spain
6.3.1.3.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
6.3.1.4. Italy
6.3.1.4.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
6.3.1.5. France
6.3.1.5.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
6.3.1.6. Rest of Europe
6.3.1.6.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
7. Asia Pacific Angina Pectoris Treatment Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
7.3. Angina Pectoris Treatment Market: By Region, 2020-2030, USD (Million)
7.3.1. Asia Pacific
7.3.1.1. China
7.3.1.1.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.2. Japan
7.3.1.2.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.3. India
7.3.1.3.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.4. Australia
7.3.1.4.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.5. South Korea
7.3.1.5.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.6. Rest of Asia Pacific
7.3.1.6.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
8. Latin America Angina Pectoris Treatment Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
8.3. Angina Pectoris Treatment Market: By Region, 2020-2030, USD (Million)
8.3.1. Latin America
8.3.1.1. Brazil
8.3.1.1.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.2. Mexico
8.3.1.2.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.3. Rest of Latin America
8.3.1.3.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
9. Middle East and Africa Angina Pectoris Treatment Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
9.3. Angina Pectoris Treatment Market: By Region, 2020-2030, USD (Million)
9.3.1. Middle East and Africa
9.3.1.1. GCC
9.3.1.1.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
9.3.1.2. Africa
9.3.1.2.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
9.3.1.3. Rest of Middle East and Africa
9.3.1.3.1. Angina Pectoris Treatment Market: By Drug Class, 2020-2030, USD (Million)
10. Company Profile
10.1. Abbott Laboratories Inc.
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Portfolio
10.1.4. Strategic Initiatives
10.2. Astra Zeneca plc
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Portfolio
10.2.4. Strategic Initiatives
10.3. Bayer AG
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Portfolio
10.3.4. Strategic Initiatives
10.4. Bristol-Myers Squibb Company
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Portfolio
10.4.4. Strategic Initiatives
10.5. F. Hoffmann-La Roche Ltd.
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Portfolio
10.5.4. Strategic Initiatives
10.6. Forest Laboratories Inc.
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Portfolio
10.6.4. Strategic Initiatives
10.7. Gilead Sciences, Inc.
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Portfolio
10.7.4. Strategic Initiatives
10.8. GlaxoSmithKline plc
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Portfolio
10.8.4. Strategic Initiatives
10.9. Novartis AG
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Portfolio
10.9.4. Strategic Initiatives
10.10. Pfizer Inc.
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Portfolio
10.10.4. Strategic Initiatives
10.11. Sanofi SA
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Portfolio
10.11.4. Strategic Initiatives
List of Figures
Figure 1 Global Angina Pectoris Treatment Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Angina Pectoris Treatment Market: Quality Assurance
Figure 5 Global Angina Pectoris Treatment Market, By Drug Class, 2021
Figure 6 Global Angina Pectoris Treatment Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Angina Pectoris Treatment Market, 2021
Figure 8 Market Positioning of Key Angina Pectoris Treatment Market Players, 2021
Figure 9 Global Angina Pectoris Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Porters Five Force Model - Current, Midterm and Long Term Perspective
Figure 11 See Saw Analysis
Figure 12 PETEL Analysis
Figure 13 Key Buying Criteria: Current and Long-Term Perspective
Figure 14 Global Angina Pectoris Treatment Market, Scenario Analysis, 2020 to 2030 (US$ Million)
Figure 15 Heptalysis Analysis: Global Angina Pectoris Treatment Market
Figure 16 Five Whys Analysis
Figure 17 Global Angina Pectoris Treatment Market, By Drug Class, 2021 Vs 2030, %
Figure 18 U.S. Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 19 Canada Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 20 Rest of North America Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 21 UK Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 22 Germany Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 23 Spain Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 24 Italy Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 25 France Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 26 Rest of Europe Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 27 China Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 28 Japan Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 29 India Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 30 Australia Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 31 South Korea Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 32 Rest of Asia Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 33 Brazil Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 34 Mexico Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 35 Rest of Latin America Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 36 GCC Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 37 Africa Angina Pectoris Treatment Market (US$ Million), 2020 - 2030
Figure 38 Rest of Middle East and Africa Angina Pectoris Treatment Market (US$ Million), 2020 - 2030List of Tables
Table 1 Global Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 2 Global Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 3 Global Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 4 North America Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 5 North America Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 6 North America Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 7 U.S. Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 8 U.S. Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 9 U.S. Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 10 Canada Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 11 Canada Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 12 Canada Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 13 Rest of North America Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 14 Rest of North America Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 15 Rest of North America Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 16 UK and European Union Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 17 UK and European Union Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 18 UK and European Union Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 19 UK Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 20 UK Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 21 UK Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 22 Germany Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 23 Germany Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 24 Germany Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 25 Spain Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 26 Spain Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 27 Spain Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 28 Italy Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 29 Italy Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 30 Italy Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 31 France Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 32 France Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 33 France Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 34 Rest of Europe Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 35 Rest of Europe Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 36 Rest of Europe Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 37 Asia Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 38 Asia Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 39 Asia Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 40 China Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 41 China Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 42 China Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 43 Japan Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 44 Japan Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 45 Japan Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 46 India Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 47 India Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 48 India Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 49 Australia Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 50 Australia Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 51 Australia Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 52 South Korea Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 53 South Korea Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 54 South Korea Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 55 Latin America Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 56 Latin America Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 57 Latin America Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 58 Brazil Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 59 Brazil Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 60 Brazil Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 61 Mexico Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 62 Mexico Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 63 Mexico Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 64 Rest of Latin America Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 65 Rest of Latin America Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 66 Rest of Latin America Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 67 Middle East and Africa Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 68 Middle East and Africa Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 69 Middle East and Africa Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 70 GCC Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 71 GCC Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 72 GCC Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 73 Africa Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 74 Africa Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 75 Africa Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Table 76 Rest of Middle East and Africa Angina Pectoris Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 77 Rest of Middle East and Africa Angina Pectoris Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
Table 78 Rest of Middle East and Africa Angina Pectoris Treatment Market By Projected sales of Phase III Drugs estimated till 2030 (US$ Mn), 2020-2030, USD (Million)
Companies Mentioned
- Abbott Laboratories Inc.
- Astra Zeneca plc
- Bayer AG
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Forest Laboratories Inc.
- Gilead Sciences Inc.
- GlaxoSmithKline plc
- Novartis AG
- Pfizer Inc.
- Sanofi SA
